Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rare Neurodegenerative Disorders Share DNA Repeat Mutation

By LabMedica International staff writers
Posted on 29 Jul 2019
Genomics researchers have found that at least four rare neurodegenerative diseases result from CGG (cytosine-guanine-guanine) repeat mutations the DNA located in distant, seemingly unrelated areas of the genome.

Noncoding repeat expansions cause various neuromuscular diseases, including myotonic dystrophies, fragile X tremor/ataxia syndrome, some spinocerebellar ataxias, amyotrophic lateral sclerosis, and benign adult familial myoclonic epilepsies.

Inspired by the striking similarities in the clinical and neuroimaging findings between neuronal intranuclear inclusion disease (NIID) and fragile X tremor/ataxia syndrome caused by noncoding CGG repeat expansions in the FMR1 (fragile X mental retardation 1) gene, investigators at the University of Tokyo (Japan) used advanced next-generation genome sequencing and data analysis techniques to search directly for repeat expansion mutations.

Results of the DNA sequencing study identified noncoding CGG repeat expansions in the NBPF19 (Neuroblastoma breakpoint family member 19) gene as the causative mutations for NIID. More...
NIID is a slowly progressive, neurodegenerative disease that may affect any part of the nervous system (central, peripheral, and/or autonomic), as well as various organs. The features of NIID result from the presence of eosinophilic intranuclear inclusions inside neurons and glial cells. Both sporadic and familial cases have been reported. However, specific genes known to cause NIID had not previously been found.

Further prompted by the similarities in the clinical and neuroimaging findings with NIID, the investigators identified similar noncoding CGG repeat expansions in two other diseases: oculopharyngeal myopathy with leukoencephalopathy and oculopharyngodistal myopathy.

"Because the mutations causing the diseases are so similar, in the future, all these patients might benefit from the same treatment," said first author Dr. Hiroyuki Ishiura, an assistant professor at the University of Tokyo Hospital.

The study was published in the July 22, 2019, online edition of the journal Nature Genetics.

Related Links:
University of Tokyo


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.